甘露聚糖肽联合匹多莫德对反复呼吸道感染患儿炎症指标、免疫功能的影响及安全性分析  

Effect of mannan peptide combined with pidotimod on inflammatory indicators,immune function and safety in children with repeated respiratory tract infection

作　　者：宫铁锋 方彬[1] 任会利 祁为 GONG Tiefeng;FANG Bin;REN Huili;QI Wei(Department of Respiratory Medicine,Zhuozhou Hospital,Zhuozhou,Hebei072750,China)

机构地区：[1]涿州市医院呼吸内科

出　　处：《国际检验医学杂志》2019年第16期1963-1967,共5页International Journal of Laboratory Medicine

基　　金：保定市科技计划项目(18ZF225)

摘　　要：目的探讨甘露聚糖肽联合匹多莫德对反复呼吸道感染(RRTI)患儿炎症指标、免疫功能的影响及安全性。方法选择2016年8月至2017年10月该院收治的96例RRTI患儿作为研究对象。应用随机数字表法将患者分为研究组和对照组,每组48例,所有患儿均进行常规对症治疗,在此基础上给予对照组患儿匹多莫德治疗,研究组患儿在对照组的基础上联合甘露聚糖肽治疗。比较两组患儿症状体征持续时间,临床疗效,免疫球蛋白A(IgA)、免疫球蛋白M(IgM)及免疫球蛋白G(IgG)等免疫指标水平,白细胞(WBC)、肿瘤坏死因子-α(TNF-α)、降钙素原(PCT)及中性粒细胞比例(NEUT)变化,CD3^+、CD4^+及CD4^+/CD8^+等T淋巴细胞亚群变化,血清中γ-干扰素(IFN-γ)、白细胞介素-4(IL-4)水平,不良反应。结果两组患儿治疗后症状体征持续时间有明显差异,且研究组症状体征持续时间明显短于对照组,差异有统计学意义(P<0.05);两组患儿治疗后临床疗效存在明显差异,且研究组总有效率明显高于对照组,差异有统计学意义(P<0.05);两组患儿治疗后IgA、IgM及IgG等免疫指标水平较治疗前均明显升高,且研究组上升更明显,差异有统计学意义(P<0.05);两组患儿治疗后WBC、TNF-α、PCT及NEUT较治疗前均明显降低,且研究组下降更明显,差异有统计学意义(P<0.05);两组患儿治疗后CD3^+、CD4^+、CD4^+/CD8^+及血清中IFN-γ含量较治疗前均明显升高,且研究组上升更明显,差异有统计学意义(P<0.05);两组患儿治疗后血清中IL-4含量较治疗前均明显降低,且研究组下降更明显,差异有统计学意义(P<0.05)。治疗及随访期间,两组患儿均未出现明显不良反应,血常规、尿常规、心电图等检查均无异常。结论甘露聚糖肽联合匹多莫德可有效抑制RRTI患儿体内炎性反应,提高免疫能力,改善患儿临床症状体征,且安全性高,值得临床推广使用。Objective To investigate the effect of mannan peptide combined with pidotimod on inflammatory index,immune function and safety in children with recurrent respiratory tract infection(RRTI).Methods A total of 96 children with RRTI admitted to our hospital from August 2016 to October 2017 were selected as the study subjects.The patients were divided into study group and control group by random number table method,48 cases in each group were treated with routine symptomatic treatment.On this basis,the patients in control group were treated with Pidotimod.The patients in study group were treated with mannan peptide on the basis of control group.The duration of symptoms and signs,clinical efficacy,immunoglobulin A(IgA),immunoglobulin M(IgM)and immunoglobulin G(IgG)levels,white blood cell(WBC),tumor necrosis factor-alpha(TNF-alpha),procalcitonin(PCT)and neutrophil ratio(NEUT)changes,CD3^+,CD4^+and CD4^+/CD8^+T lymphocyte subsets in serum were compared between the two groups.Contents of interferon-gamma(IFN-γ)and interleukin-4(IL-4);adverse reactions.Results The duration of symptoms and signs in the two groups was significantly different after treatment,and the duration of symptoms and signs in the study group was significantly shorter than that in the control group(P<0.05);there was a significant difference in clinical efficacy between the two groups after treatment,and the total effective rate in the study group was significantly higher than that in the control group,the difference was significant.Significant difference(P<0.05);the levels of IgA,IgM,IgG and other immune indicators in the two groups after treatment were significantly higher than those before treatment,and the increase in the study group was more significant(P<0.05);WBC,TNF-α,PCT and NEUT in the two groups after treatment were significantly lower than those before treatment,and the decrease in the study group was more significant(P<0.05);CD3^+,CD4^+,CD4^+/CD8^+and serum in the two groups after treatment were significantly lower than before treatment.Th

关 键 词：反复呼吸道感染 甘露聚糖肽 匹多莫德 免疫功能 安全性 

分 类 号：R725.6[医药卫生—儿科]